Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effectiveness of a screening program for hepatitis C.

Ramsey C Cheung1, Barbara A Cunningham, Allen D Cooper

  • 1Division of Gastroenterology and Hepatology, VA Palo Alto Health Care System (154C), 3801 Miranda Ave, Palo Alto, California 94304, USA. rcheung@stanford.edu

Digestive Diseases and Sciences
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies.

Gastro hep advances·2026
Same author

No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma Among Treatment Naïve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted Analysis.

Journal of clinical and experimental hepatology·2025
Same author

Comparison of Referral Rates and Costs Using Fibrosis-4 and Enhanced Liver Fibrosis (ELF) Testing Strategies for Initial Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population.

The journal of applied laboratory medicine·2025
Same author

Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma.

Gastroenterology research·2024
Same author

Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis.

Journal of viral hepatitis·2024
Same author

On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B.

JHEP reports : innovation in hepatology·2023

Hepatitis C virus (HCV) screening in veterans showed low treatment eligibility. Many patients missed appointments or had contraindications, highlighting challenges in HCV care and follow-up.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection remains a significant public health concern, particularly among veteran populations.
  • Screening programs aim to identify infected individuals for timely treatment and improved outcomes.
  • Challenges in patient engagement and treatment eligibility can impact the effectiveness of HCV screening initiatives.

Purpose of the Study:

  • To evaluate the outcomes of a screening program for hepatitis C virus (HCV) infection among veterans.
  • To determine the proportion of screened veterans who were eligible for antiviral therapy.
  • To assess the impact of appointment adherence and follow-up on treatment candidacy.

Main Methods:

  • Retrospective analysis of 536 veterans screened for HCV infection between July 2000 and June 2001.

Related Experiment Videos

  • Assessment of initial appointment attendance, viremia status, and treatment eligibility.
  • Evaluation of outcomes for veterans who missed initial appointments and were followed up over two years.

    • Main Results:

    • Only 48.5% of HCV antibody-positive veterans attended their initial appointments.
    • Of those attending, only 9.1% were viremic and treatment-eligible.
    • Over two years, 25% of those initially lost to follow-up became treatment-eligible, resulting in 57 total treatment candidates.

    Conclusions:

    • Most veterans testing positive for HCV antibodies did not attend initial appointments or were ineligible for treatment.
    • Long-term follow-up identified additional treatment candidates, but many still had contraindications.
    • Improving patient adherence and addressing treatment contraindications are crucial for successful HCV screening programs.